RxElite, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXEI research report →
Price Chart
About the company
RxElite, Inc. is a pharmaceutical company that specializes in the development, production, and commercialization of generic prescription drugs, particularly within specialty markets. Its diverse product portfolio encompasses Sterile Liquid Dose offerings, such as generic ophthalmic solutions (available in both unit-dose and multi-dose formats), sterile unit-dose respiratory inhalation products, and various injectable medications.
- CEO
- Richard Tener
- IPO
- 2020
- Employees
- 47
- HQ
- Meridian, ID, US
Get TickerSpark's AI analysis on RXEI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.48K
- P/E
- -0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.58
- Div Yield
- 0.00%
- Gross Margin
- 5.12%
- Op Margin
- 436.80%
- Net Margin
- -610.52%
- ROE
- -273.67%
- ROIC
- 84.12%
Latest fiscal year · YoY change
- Revenue
- $2.81M+139.0%
- Gross Profit
- $144.00K-80.6%
- Op Income
- $12.28M
- Net Income
- $-17,165,275-18363.7%
- EPS
- $-0.27-3100.0%
- OCF Growth
- -18717.7%
- FCF Growth
- -25487.9%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 6.40
- RSI (14)
- 52
- Avg Volume
- 82
No earnings-call transcripts are available for RXEI yet.
- Free Float
- 79.0%
- Shares Outstanding
- 14.83M
- Float Shares
- 11.71M
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 4, 08 | RECTOR DAVID | other | 100,000 |
| Jun 4, 08 | RECTOR DAVID | other | 1,000,000 |
| Jun 4, 08 | RECTOR DAVID | sell | 400,000 |
| Jun 4, 08 | AUERBACH MARK | other | 100,000 |
| Jun 4, 08 | AUERBACH MARK | other | 1,000,000 |
| Jun 4, 08 | AUERBACH MARK | sell | 400,000 |
| Oct 11, 07 | RECTOR DAVID | other | 400,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RXEI coverage
Recent articles, reports, and earnings notes.
No research on RXEI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RXEI report →